Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: RP; REPCF

Regenerative Medicine Firm Advances Multifaceted Pipeline
News Update

Source:

The company continues advancing its cell therapies and medical device.

RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) announced in a news release the status of its various programs.

Regarding its RCI-02 dermal injector, the biotech received the functional prototype and its related consumables, which it will showcase at the annual general meeting this month. The company expects the commercial prototypes to be available in Q4/19, after which it will launch testing of them. Also underway, RepliCel is planning both its application for a CE Mark for RCI-02 and also launch of the product next year.

As for RCT-01, RepliCel's cell therapy for chronic Achilles tendinopathy, the company plans to follow up the phase 1 trial in Japan with a next phase trial, also in that country and is completing the requisite consultations to do so. With approval, the trial could begin next year and if successful, product commercialization could occur in late 2021 or early 2022. Accordingly, RepliCel is preparing the trial design and protocols.

With respect to RCS-01, RepliCel's cell therapy for skin aging and sun damage, the life sciences firm intends to conduct the next phase of trials in Japan once the RCI-02 device and consumables are available there. The company is currently planning the next clinical study with an eye toward product commercialization in Japan in the late 2021 or early 2022 time frame.

Concerning RCH-01, RepliCel's cell therapy for androgenic alopecia, an announcement from Shisheido is expected soon on whether it will next take the product to market or pursue additional testing.

Looking forward, RepliCel intends to pursue two kinds of transactions in the near term. One involves the distribution and/or licensing of its dermal injector and consumables. The other pertains to the licensing, investment and/or establishment of a joint venture for its tendon repair and skin rejuvenation cell therapy programs and its dermal injector, with a focus on Japan.

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.




Want to read more about Medical Devices and Regenerative Medicine investment ideas?
Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe